Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

PURPOSE: To assess adherence and persistence with palbociclib therapy in patients with HR+/HER2- metastatic breast cancer (mBC) in a US real-world setting. METHODS: This retrospective study evaluated palbociclib dosing, adherence, and persistence using commercial and Medicare Advantage with Part D c...

Descripción completa

Detalles Bibliográficos
Autores principales: Engel-Nitz, Nicole M, Johnson, Mary G, Johnson, Michael P, Cha-Silva, Ashley S, Kurosky, Samantha K, Liu, Xianchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122484/
https://www.ncbi.nlm.nih.gov/pubmed/37096162
http://dx.doi.org/10.2147/PPA.S401480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122484/
https://www.ncbi.nlm.nih.gov/pubmed/37096162
http://dx.doi.org/10.2147/PPA.S401480

Ejemplares similares